Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report

Anna Mair; Armin Muigg; Günther Stockhammer; Stephanie Mangesius; Dominik Wolf; Eberhard Gunsilius

doi:10.1159/000518528

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report

Case Rep Oncol. 2021 Sep 20;14(3):1337-1341. doi: 10.1159/000518528. eCollection 2021 Sep-Dec.

Authors

Anna Mair¹, Armin Muigg², Günther Stockhammer², Stephanie Mangesius³, Dominik Wolf¹, Eberhard Gunsilius¹

Affiliations

¹ Department of Hematology & Medical Oncology, Medical University Innsbruck, Innsbruck, Austria.
² Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
³ Department of Neuroradiology, Neuroimaging core facility, Medical University Innsbruck, Innsbruck, Austria.

Abstract

Primary CNS lymphoma (PCNSL) is a highly aggressive malignant disease with a high recurrence rate and a poor prognosis. We present the case of a 71-year-old woman diagnosed with PCNSL in June 2010. After 3 relapses and intensive treatment with multiple chemotherapy regimens and whole-brain radiotherapy, she received off-label treatment with the Bruton tyrosine kinase inhibitor ibrutinib, responded well, achieved a complete remission, and is progression-free for now >3 years.

Keywords: Ibrutinib; Primary CNS lymphoma.

Publication types

Case Reports